Guidelines

Table 24f. Drug Interactions Between HIV-1 gp120-Directed Attachment Inhibitors and Other Drugs (Including Antiretroviral Agents) Fostemsavir (FTR), an HIV-1 gp120-directed attachment inhibitor, is a prodrug of temsavir (TMR). In this table, the effect on gp120-directed attachment inhibitor refers to TMR concentrations. Recommendations for managing a particular drug interaction may differ depending on whether a new …

HIV-1 gp120-Directed Attachment Inhibitors Read More »

Table 25a. Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors Note: Interactions associated with DLV, FPV, IDV, NFV, TPV, and SQV are not included in this table. Please refer to the Food and Drug Administration product labels for information regarding interactions between these drugs and other concomitant drugs. Rilpivirine (RPV) intramuscular (IM) is not included in this …

Interactions between PIs and NNRTIs Read More »

AU Comment: INSTI and NNRTI regimen switches INSTI metabolism via CYP3A4, concurrent use with inducers results in diminished INSTI plasma concentration – advise caution when switching from NNRTI-based to INSTI-based ART regimens due to NNRTI half-life and resolution of induction effect AU Comment: Etravirine and cobicistat boosted Integrase regimens Etravirine (ETR) is not recommended in …

Interactions between INSTI & NNRTI or PI Read More »

This section has information on Limitations to Treatment Safety & Efficacy. Please click on the below links or follow the table of contents to access the information you are looking for. Cost Considerations and ART Adherence to the Continuum of Care Adverse Effects of ARV Agents

AU Comment: Australian data on rates of virological suppression Data from the 2022 Annual Surveillance Report estimates at the end of 2021, there were 29 460 people living with HIV in Australia. Of these an estimated 91% (26 830) had been diagnosed. Of those diagnosed at the end of 2021, an estimated 96% (25 820) …

Adherence to the Continuum of Care Read More »

AU Comment: Weight gain and INSTIs Several reports have identified associations between the use of integrase strand transfer inhibitors (INSTIs) and increased weight and/or body mass index (BMI). It is unclear if this is a causal relationship or is associated with increased morbidity from conditions typically associated with increased weight such as type 2 diabetes …

Adverse Effects of ARV Agents Read More »

AU Comment: Cost considerations and ART in the Australian context The Australian Government provides fully subsidised ARV drugs under the Highly Specialised Drugs (HSD) Program. To gain access to a Commonwealth funded drug under this program, a patient must be an Australian resident in Australia (or other eligible person) and have a Medicare card. Patients …

Cost Considerations and ART Read More »

This section has information on Considerations for Antiretroviral Use in Patients with Coinfections. Please click on the below links or follow the table of contents to access the information you are looking for. TB/HIV HBV/HIV HCV/HIV

AU Comment: Australian epidemiology Approximately 5% of Australia’s 26,500 people with HIV also have chronic hepatitis B. Reference: GESA Australian consensus recommendations for the management of hepatitis B infection Panel’s Recommendations Regarding Hepatitis B Virus/ HIV Coinfection Panel’s Recommendations Before initiation of antiretroviral therapy (ART), all patients who test positive for hepatitis B surface antigen …

HBV/HIV Read More »

AU Comment: Hepatitis C Treatment in the Australian Context The PBS lists the following all-oral pan genotypic regimens for the treatment of chronic hepatitis C infection in Australia, regardless of liver disease stage or ongoing drug and alcohol use. Treatment naïve: Sofosbuvir  + Velpatasvir OR Glecaprevir + Pibrentasvir Treatment experienced: sofosbuvir+velpatasvir+ voxilaprevir (Vosevi) Regimens should …

HCV/HIV Read More »